Navigation Links
H1N1 Influenza Virus With Highest Replikin Count(TM) Since the 1918 Pandemic Identified in the U.S. and Austria
Date:4/7/2008

BOSTON, April 7, 2008 /PRNewswire/ -- Replikins Ltd. has found that the Replikin Count(TM) of the H1N1 strain of influenza virus has recently increased to 7.6 (plus/minus 1.4), its highest level since the 1918 H1N1 pandemic (p value less than 0.001). A rising Replikin Count of a particular influenza strain, indicating rapid replication of the virus, is an early warning which has been followed consistently by an outbreak of the specific strain. The current increase appears to be specific to H1N1; there was a concurrent 80% decline in the Replikin Count of H3N2, for instance.

The current H1N1 appears to be rapidly replicating simultaneously in the U.S. and Austria. It may succeed H5N1 as the leading candidate for the next expected overdue pandemic. However, the same virus replikin structures detected by FluForecast(R) software in all three previous pandemics, namely 1918 H1N1, 1957 H2N2, and 1968 H3N2, as well as in H5N1, have not yet been detected in the currently evolving H1N1.

There is evidence that many factors, including virus structure, host receptivity, and the environment, together with infectivity and rapid replication, need to converge for a pandemic to occur. For H5N1, the high human mortality rate, which peaked at over 80% in 2006-07 in Indonesia, as well as current low infectivity, both appear to limit H5N1's ability to produce a pandemic. Furthermore, the H5N1 rapid replication cycle which began in 1996 now appears to be over. The H5N1 virus produced less than 300 World Health Organization confirmed deaths over the past 10 years.

On the other hand, H1N1, with an estimated human mortality rate of only 2.5 to 10%, but with much higher infectivity, produced an estimated 50 million deaths in the 1918 pandemic. A number of countermeasures exist today which did not exist in 1918, however. Among these is Replikins' ability to manufacture synthetic vaccines based on current sequences, with a 7-day production turnaround.

Contact:

Replikins Ltd., 38 The Fenway, Boston MA 02215

email: sbogoch@replikins.com

Tel: 646-320-5910

http://www.Replikins.com

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Replikins Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Childhood Influenza Immunization Coalition Applauds Expanded Influenza Vaccine Recommendation for Children
2. NIH Funds Vaccine Research for Needle-free and Self-Administered Protection Against Pandemic Influenza
3. GelVac(TM) Nasal Powder H5N1 (Bird Flu) Influenza Vaccine Passes Preclinical Toxicology Studies
4. Vical to Participate in Pandemic Influenza Panel at JPMorgan Healthcare Conference
5. Sinovac Reports Top-Line Preliminary Phase II Results of Pandemic Influenza (H5N1) Whole Viron Vaccine
6. Lethal Human H5N1 Influenza Virus Replikin Gene Still Upregulated
7. Vical Presentation at Military Pandemic Influenza Workshop
8. Enigma Diagnostics Announces a European Commission Award of EUR3 Million to Fund the Development of a Point of Care Platform for the Rapid Diagnosis of Influenza Infections
9. Protherics Licenses its CoVaccine HT Adjuvant to Nobilon for Influenza Vaccine Indications
10. European Expert Consortium Combines Forces to Develop a Novel Pandemic Influenza Vaccine
11. BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 27, 2016  Sequenom, Inc. (NASDAQ: SQNM ... lives through the development of innovative products and services, ... the United States denied its petition to ... of Sequenom,s U.S. Patent No. 6,258,540 (",540 Patent") are ... by the Supreme Court,s Mayo Collaborative Services v. Prometheus ...
(Date:6/27/2016)... June 27, 2016  Liquid Biotech ... funding of a Sponsored Research Agreement with The ... cells (CTCs) from cancer patients.  The funding will ... levels correlate with clinical outcomes in cancer patients ... will then be employed to support the design ...
(Date:6/24/2016)... ... 24, 2016 , ... Researchers at the Universita Politecnica delle Marche in Ancona ... or pleural mesothelioma. Their findings are the subject of a new article on the ... are signposts in the blood, lung fluid or tissue of mesothelioma patients that can ...
(Date:6/23/2016)... SILVER SPRING, Md. , June 23, 2016 ... evidence collected from the crime scene to track the criminal ... sick, and the U.S. Food and Drug Administration (FDA) uses ... Sound far-fetched? It,s not. ... whole genome sequencing to support investigations of foodborne illnesses. Put ...
Breaking Biology Technology:
(Date:6/2/2016)... -- Perimeter Surveillance & Detection Systems, Biometrics ... Support & Other Service  The latest report ... analysis of the global Border Security market . ... $17.98 billion in 2016. Now: In November ... software and hardware technologies for advanced video surveillance. ...
(Date:5/16/2016)... , May 16, 2016   EyeLock LLC , ... announced the opening of an IoT Center of Excellence ... and expand the development of embedded iris biometric applications. ... level of convenience and security with unmatched biometric accuracy, ... identity aside from DNA. EyeLock,s platform uses video technology ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... of Infosys (NYSE: INFY ), and Samsung SDS, ... partnership that will provide end customers with a more ... payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) ... financial services, but it also plays a fundamental part in ...
Breaking Biology News(10 mins):